GLP-1 Dosage for Weight Loss: FDA-Labeled Titration Schedules

What GLP-1 dosage for weight loss means (general information)

Starting a GLP-1 treatment plan involves several moving parts: dosing schedules, titration timelines, and maintenance targets all require attention before treatment begins. These medications follow a clear, evidence-based titration framework, and understanding how that framework works helps patients set realistic expectations.

GLP-1 receptor agonist medications mimic glucagon-like peptide-1, a natural hormone that regulates hunger and blood sugar. The FDA approves several of these medications for chronic weight management in adults with a body mass index (BMI) of 30 or higher, and in adults with a BMI of 27 or higher who also have a weight-related condition such as type 2 diabetes or cardiovascular disease.

Semaglutide, tirzepatide, and other GLP-1 receptor agonists reduce appetite and slow digestion, which prolongs the feeling of fullness. Depending on the specific medication a clinician prescribes, they are given by subcutaneous injection or as an oral tablet.

How titration works

Dosing schedules for GLP-1 medications follow a titration process: the dose starts low and increases gradually over weeks or months. This stepwise approach gives the body time to adjust and helps reduce common early side effects such as nausea and digestive discomfort. Every dose change belongs with the prescribing clinician, who follows the medication's FDA-labeled schedule.

FDA-labeled titration schedules at a glance

Each GLP-1 medication follows its own FDA-labeled titration path. The table below summarizes the labeled schedules for the major options approved for weight management.

The oral Wegovy tablet is a once-daily form of semaglutide, taken on an empty stomach with no more than 4 oz of water and at least 30 minutes before eating or taking other medications. That is a different schedule from the once-weekly Wegovy injection, and a clinician determines which formulation and schedule are appropriate.

Patients who reach the standard 2.4 mg Wegovy maintenance dose and still need additional support have an FDA-approved higher-dose option. The FDA approved the 7.2 mg Wegovy injection in March 2026 as the highest-dose option. Under the FDA label, the 7.2 mg dose may be used only after a patient has tolerated the 2.4 mg dose for at least four weeks and further weight reduction is clinically indicated. In the trial reported in the label, patients on 7.2 mg lost a mean of 18.8% of body weight at week 72, compared with 15.5% on 2.4 mg and 3.9% on placebo, and 45.5% of those on 7.2 mg lost 20% or more.

Research indicates that continuing GLP-1 medications long term is associated with better weight-management outcomes, and weight is often regained after stopping, which is why ongoing management is typically part of a long-term plan.

Dosing for MASH

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver condition involving significant scarring. Wegovy (semaglutide) is approved under FDA accelerated approval for noncirrhotic MASH with moderate-to-advanced liver fibrosis. For this indication, the labeled maintenance dose is 2.4 mg once weekly, and the label states the dose can be decreased to 1.7 mg once weekly if the 2.4 mg dose is not tolerated. It is not indicated for MASH with cirrhosis.

Safety, side effects & contraindications

GLP-1 receptor agonists such as semaglutide and tirzepatide carry both common and serious side effects that patients should understand before starting treatment.

Common side effects

Most people experience mild symptoms when beginning the medication or increasing the dose. These commonly include:

• Reduced appetite
• Nausea
• Vomiting
• Diarrhea
• Constipation

These digestive symptoms often ease as the body adjusts. According to FDA labeling, rare but serious risks include acute pancreatitis and acute kidney injury, and the labels carry a boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma, based on rodent studies. The FDA-labeled titration schedules for medications such as Ozempic and Mounjaro call for gradual dose increases in part to reduce gastrointestinal side effects.

Why the titration schedule matters

The FDA-labeled schedules increase the dose gradually specifically so the body can adapt and early gastrointestinal side effects stay milder. Following the labeled schedule, under a prescriber's direction, is the approach the labels describe for limiting nausea and related symptoms during dose escalation. Because the pace of escalation is set by the label and the prescriber, patients should not accelerate or skip steps on their own.

Who should not take GLP-1 medications

GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). The FDA labeling also advises caution for people with any of the following:

• Dehydration or diabetic retinopathy
• Severe gastrointestinal disease, including severe gastroparesis
• Kidney disease or a history of pancreatitis
• Diabetic ketoacidosis or type 1 diabetes

Special populations and drug interactions

Older adults may be more sensitive to semaglutide's effects. Wegovy is indicated for adults and pediatric patients aged 12 and older with obesity; it is not approved for children under 12. GLP-1 medications should be avoided in pregnancy, and the labeling advises discontinuing semaglutide at least two months before a planned pregnancy because of its long clearance and animal findings suggesting potential developmental effects.

Because GLP-1 medications slow gastric emptying, they can affect the absorption of some oral medications, and dose adjustments may be needed for insulin or other glucose-lowering drugs. Patients should tell their clinician about every medication they take before starting GLP-1 therapy. Injection-site reactions can also occur. Before starting treatment, a full review of medical history, current medications, and lifestyle factors with a primary care clinician or endocrinologist is a foundational step for safe use.

What to ask your clinician

Patients benefit from asking specific questions about GLP-1 dosing and treatment plans. Because every dose decision belongs with a prescriber, these questions can help guide that conversation.

1. Ask about the FDA-labeled titration schedule for the specific GLP-1 receptor agonist prescribed, whether it is Wegovy, Rybelsus, Zepbound, or another brand.
2. Ask when the clinician plans to increase the dose after the initial adjustment period, since dose escalation follows the labeled schedule.
3. Ask what signs indicate the current dose is not working, such as a weight-loss plateau despite diet and activity changes.
4. Ask how to recognize returning hunger or intrusive food thoughts, which may prompt a clinician to reassess the dose.
5. Discuss which early side effects, such as nausea or constipation, typically resolve on their own versus those that need medical attention.
6. Ask about a schedule for follow-up visits to monitor effectiveness and side effects.
7. Ask about switching from the oral tablet to the injectable form, or between GLP-1 medications, since any change requires specific medical guidance.
8. Ask what to do if a dose is missed, since the clinician will advise how to resume treatment safely.
9. Tell the clinician if pregnancy is planned, since GLP-1 medications should be stopped before conception.
10. Ask whether household members should understand how to help manage side effects.

Frequently asked questions

Do GLP-1 medications cause low blood sugar on their own?

Generally no. GLP-1 receptor agonists such as semaglutide do not, by themselves, typically cause hypoglycemia. Low blood sugar becomes more likely when they are combined with insulin or sulfonylureas, so patients on those combinations should monitor their levels with a clinician's guidance.

What is the standard starting dose for semaglutide?

For Wegovy injection, the FDA-labeled schedule starts at 0.25 mg once weekly for four weeks, then increases gradually (0.5 mg, 1 mg, 1.7 mg) to a 2.4 mg once-weekly maintenance dose. Patients should follow the labeled schedule under a clinician's direction and never adjust the dose on their own.

Is it safe to share injection pens or syringes?

No. Pens and syringes should never be shared, because sharing them carries a serious risk of transmitting infections.

Can semaglutide reduce the risk of heart attack and stroke?

Yes. In the SUSTAIN-6 cardiovascular outcomes trial, semaglutide reduced the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, and nonfatal stroke) in adults with type 2 diabetes and established cardiovascular disease. This is one reason semaglutide now carries cardiovascular indications beyond blood-sugar control.

Does semaglutide help protect the kidneys?

In the FLOW trial, semaglutide reduced the risk of a composite kidney-and-cardiovascular outcome by 24% compared with placebo in people with type 2 diabetes and chronic kidney disease. The composite included kidney-function decline, kidney failure, and death from kidney or cardiovascular causes. It is a data point worth discussing with a care team.

Which medications should not be combined with semaglutide?

Semaglutide should not be combined with another GLP-1 receptor agonist such as dulaglutide, liraglutide, or tirzepatide. Using more than one GLP-1 receptor agonist at once raises the risk of side effects without adding benefit.

What conditions does semaglutide treat?

Depending on the product, semaglutide is approved for type 2 diabetes, cardiovascular risk reduction, and chronic weight management, and Wegovy is approved for noncirrhotic MASH with moderate-to-advanced fibrosis. It is not indicated for MASH with cirrhosis.

How does prior authorization work for GLP-1 therapy?

Prior authorization may be required before starting GLP-1 treatment, so patients should discuss coverage with their clinician and insurer early. Separately, starting July 1, 2026, the CMS Medicare GLP-1 Bridge lets eligible Medicare Part D enrollees access certain GLP-1 medications for a flat $50 monthly copay, through December 31, 2027. Eligible patients can ask their clinician or insurer whether the program applies to them.